Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Preclinical and clinical studies indicate safety and efficacy of SB-209509/VML-251 for migraine

June 19, 1997

Preclinical studies reported for rizatriptan

June 19, 1997

Almotriptan: a novel antimigraine agent from Almirall

June 19, 1997

Preclinical profile of novel migraine abortive from BMS

June 19, 1997

Targets for antimigraine therapy: antiepileptic drugs in the treatment of migraine

June 19, 1997

Novel CCK-B antagonist with anxiolytic activity from Rotta

June 18, 1997

High-dose riboflavin for migraine prophylaxis

June 18, 1997

Targets for antimigraine therapy: SSRIs in the prevention of migraine

June 18, 1997

Targets for antimigraine therapy: NOS inhibitors as new therapeutic approach

June 18, 1997

Targets for antimigraine therapy: NK1 blockade not an effective antimigraine strategy

June 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...